News25/Ratings0
Price$0.63-6.82 (-91.48%)
2026-01-282026-05-01
News · 26 weeks38-38%
2025-11-022026-04-26
Mix2690d
- SEC Filings14(54%)
- Other6(23%)
- Insider6(23%)
Latest news
25 items- SECSEC Form S-1 filed by Onconetix Inc.S-1 - Onconetix, Inc. (0001782107) (Filer)
- SECOnconetix Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Onconetix, Inc. (0001782107) (Filer)
- INSIDERSEC Form 4 filed by Hrt Financial Lp4 - Onconetix, Inc. (0001782107) (Issuer)
- INSIDERSEC Form 4 filed by Hrt Financial Lp4 - Onconetix, Inc. (0001782107) (Issuer)
- INSIDERSEC Form 4 filed by Hrt Financial Lp4 - Onconetix, Inc. (0001782107) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hrt Financial Lp3 - Onconetix, Inc. (0001782107) (Issuer)
- SECSEC Form 425 filed by Onconetix Inc.425 - Onconetix, Inc. (0001782107) (Subject)
- PROnconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to EricssonVinci Enables Realbotix Robots to Recognize People, Recall Conversations, and Track Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, April 09, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix's previously announced pending acquisition. On April 8, 2026, Realbotix announced that it has delivered its first Vinci-equipped humanoid robot to Ericsson. Vinci is a patented AI vision system that allows the robot to recognize
- SECSEC Form 425 filed by Onconetix Inc.425 - Onconetix, Inc. (0001782107) (Subject)
- PROnconetix Highlights Realbotix AI Humanoid Robot Delivery UpdateRealbotix Announces Expected Delivery of 19 Robots in March, April, and May 2026 as it Scales Production Capacity; Onconetix recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a subsidiary of Realbotix Corp. CINCINNATI, Ohio, April 02, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix's previously announced pending acquisition. On April 1, 2026, Realbotix announced that it expects to deliver 19 previously ordered robots and corresponding AI implementations for months of March, April, and
- SECSEC Form 425 filed by Onconetix Inc.425 - Onconetix, Inc. (0001782107) (Subject)
- PROnconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of DirectorsExperienced Leadership Team Positioned to Execute Pending Transformative Acquisition of Realbotix LLC and Drive Long-Term Shareholder Value CINCINNATI, Ohio, March 31, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") today announced the appointment of David White as Chief Executive Officer, effective March 18, 2026, and the appointment of Sammy Dorf as a member of the Company's Board of Directors and the Audit Committee, effective March 19, 2026. Karina Fedasz, the Company's outgoing Interim Chief Executive Officer, will continue to serve as its Interim Chief Financial Officer. These appointments reflect the Company's commitment to assembling experien
- SECSEC Form DEF 14A filed by Onconetix Inc.DEF 14A - Onconetix, Inc. (0001782107) (Filer)
- INSIDERSEC Form 3 filed by new insider White David Allan3 - Onconetix, Inc. (0001782107) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dorf Sammy3 - Onconetix, Inc. (0001782107) (Issuer)
- SECSEC Form 425 filed by Onconetix Inc.425 - Onconetix, Inc. (0001782107) (Subject)
- SECAmendment: Onconetix Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K/A - Onconetix, Inc. (0001782107) (Filer)
- SECOnconetix Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Onconetix, Inc. (0001782107) (Filer)
- PROnconetix, Inc. Announces 1-for-5 Reverse Stock SplitCINCINNATI, Ohio, March 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that its Board of Directors (the "Board of Directors" or "Board") has approved a 1-for-5 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on March 25, 2026. On February 3, 2026, Onconetix held a special meeting of stockholders (the "Special Meeting"), at which the Company's stockholders approved a proposal to effect a reverse split, at a ratio in
- SECSEC Form PRE 14A filed by Onconetix Inc.PRE 14A - Onconetix, Inc. (0001782107) (Filer)
- SECSEC Form 10-K filed by Onconetix Inc.10-K - Onconetix, Inc. (0001782107) (Filer)
- SECSEC Form 425 filed by Onconetix Inc.425 - Onconetix, Inc. (0001782107) (Subject)
- SECOnconetix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Onconetix, Inc. (0001782107) (Filer)
- PROnconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics CompanyA leading AI and humanoid robotics company has commercially available models designed, built and manufactured in the United States of America CINCINNATI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:ONCO) ("Onconetix" or the "Company"), (formerly Blue Water Biotech Inc), and Realbotix LLC. ("Realbotix"), a wholly-owned subsidiary of Realbotix Corp. (TSXV:XBOT) ("Realbotix Parent "), today announced the signing of a definitive share exchange agreement pursuant to which Onconetix will acquire 100% of the issued and outstanding equity interests of Realbotix in an all-stock transaction. Realbotix LLC is Realbotix Corp's subsidiary that is focused on researching, designing, bu
- PRRealbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed IssuerRealbotix Corp. (TSXV:XBOT) (Frankfurt: 76M0.F) (OTC:XBOTF) ("Realbotix" or the "Parent Company"), a leader in AI-powered humanoid robots, announces it has entered into a definitive agreement with Onconetix, Inc (NASDAQ:ONCO) ("ONCO"), pursuant to which ONCO will acquire 100% of Realbotix, LLC ("RealLLC" or the "Subsidiary"), a wholly owned subsidiary of Realbotix in an all-stock transaction. RealLLC is a Nevada based wholly owned subsidiary of Realbotix. RealLLC focuses on the research, development, design and manufacture of AI-powered humanoid robots for use by commercial clients in consumer facing roles such as customer service, healthcare, education, hospitality and entertainment. Rea
ONCO FAQ
5 questionsWhere does ONCO stock trade?
Onconetix Inc. (ONCO) is listed on NASDAQ.What sector and industry is ONCO in?
Onconetix Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Onconetix Inc. go public?
Onconetix Inc. (ONCO) completed its IPO in 2022.What companies are similar to ONCO?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare ONCO side-by-side with any of them on Quantisnow.How can I track ONCO on Quantisnow?
Quantisnow aggregates Onconetix Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ONCO to receive live email and push alerts on every new disclosure.